ABL1 and acute lymphoblastic leukemia: In order to evaluate if this technology may represent a valid alternative to the qualitative BIOMED-1 PCR for CML and ALL patients, we analyzed a total of 122 BCR-ABL1-positive and 50 negative samples using the Q-LAMP assay.